MedTrace Logo

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

NCT07128628 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 423

Last updated 2026-03-13

No results posted yet for this study

Summary

A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease

Conditions

Interventions

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

DRUG

Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks

DRUG

Lifitegrast

Topical ocular drop of lifitegrast administered for 4 weeks

DRUG

Perfluorohexyloctane

Topical ocular drop of perfluorohexyloctane administered for 4 weeks

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

DRUG

Vehicle

Topical ocular drop with no active ingredients administered for 4 weeks

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-24
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128628 on ClinicalTrials.gov